Marshall Wace LLP Invests $2.94 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Marshall Wace LLP purchased a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 429,592 shares of the biopharmaceutical company's stock, valued at approximately $2,938,000. Marshall Wace LLP owned approximately 0.28% of Ocular Therapeutix at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Paradigm Capital Management Inc. NY boosted its position in Ocular Therapeutix by 114.3% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 300,000 shares of the biopharmaceutical company's stock valued at $2,052,000 after buying an additional 160,000 shares during the last quarter. Tri Locum Partners LP bought a new position in Ocular Therapeutix in the 2nd quarter valued at $3,520,000. Avoro Capital Advisors LLC boosted its position in Ocular Therapeutix by 12.7% in the 2nd quarter. Avoro Capital Advisors LLC now owns 8,060,000 shares of the biopharmaceutical company's stock valued at $55,130,000 after buying an additional 911,064 shares during the last quarter. HighVista Strategies LLC bought a new position in Ocular Therapeutix in the 2nd quarter valued at $423,000. Finally, Profund Advisors LLC boosted its position in Ocular Therapeutix by 263.9% in the 2nd quarter. Profund Advisors LLC now owns 43,182 shares of the biopharmaceutical company's stock valued at $295,000 after buying an additional 31,314 shares during the last quarter. 59.21% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on OCUL shares. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of Ocular Therapeutix in a research report on Thursday, August 1st. Robert W. Baird reduced their price target on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating on the stock in a research report on Thursday, August 8th. Piper Sandler restated an "overweight" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Friday, June 21st. Finally, TD Cowen lowered Ocular Therapeutix from a "strong-buy" rating to a "hold" rating in a research report on Friday, June 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Ocular Therapeutix presently has an average rating of "Moderate Buy" and an average price target of $15.67.

Ocular Therapeutix Trading Up 6.4 %

Ocular Therapeutix stock traded up $0.59 during mid-day trading on Friday, hitting $9.82. 1,090,636 shares of the company's stock were exchanged, compared to its average volume of 1,963,296. The firm has a market capitalization of $1.52 billion, a P/E ratio of -6.84 and a beta of 1.28. Ocular Therapeutix, Inc. has a fifty-two week low of $2.00 and a fifty-two week high of $11.31. The company has a quick ratio of 16.55, a current ratio of 16.64 and a debt-to-equity ratio of 0.18. The company's 50 day simple moving average is $8.57 and its 200-day simple moving average is $7.40.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.04). Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The firm had revenue of $16.40 million during the quarter, compared to analyst estimates of $15.85 million. During the same period in the prior year, the business earned ($0.27) EPS. The business's revenue for the quarter was up 7.9% compared to the same quarter last year. On average, equities analysts anticipate that Ocular Therapeutix, Inc. will post -1.02 earnings per share for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.